Kriya Therapeutics, Inc – Trademark Portfolio

Entity Type: 03

Kriya Therapeutics, Inc holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include KRIYA. The owner is based in Morrisville, NC.

4105 Hopson Rd

Morrisville, NC 27560

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

KRIYA
KRIYA
Registered 2022

Trademark Classifications

Kriya Therapeutics, Inc's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Kriya Therapeutics, Inc have?

Kriya Therapeutics, Inc has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Kriya Therapeutics, Inc file in?

Kriya Therapeutics, Inc files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Kriya Therapeutics, Inc's most well-known trademarks?

Kriya Therapeutics, Inc's registered trademark portfolio includes well-known marks such as KRIYA. These are among 1 currently registered trademark in the portfolio.

What is Kriya Therapeutics, Inc's trademark registration success rate?

Kriya Therapeutics, Inc has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.